Results 81 to 90 of about 5,492,450 (303)

TREATMENT OF TUBERCULOSIS PATIENTS WITH EXTENSIVE DRUG RESISTANCE USING NEW ANTI-TUBERCULOSIS DRUGS IN THE CIVILIAN COMMUNITY OF ARKHANGELSK REGION

open access: yesТуберкулез и болезни лёгких, 2018
The objective: to assess treatment outcomes in tuberculosis patients with extensive drug resistance (XDR TB) treated by new anti-tuberculosis drugs in the civilian community of Arkhangelsk Region.The analysis included all cases of XDR TB registered in ...
Anastasiya I. Gayda   +5 more
doaj   +1 more source

Post-translational modifications in drug resistance

open access: yes
Resistance to antitumor drugs, antimicrobial drugs, and antiviral drugs severely limits treatment effectiveness and cure rate of diseases. Protein post-translational modifications (PTMs) represented by glycosylation, ubiquitination, SUMOylation ...
Zhang, Cheng   +9 more
core   +1 more source

Conserved binding mode but diverse interfaces of MreC‐PBP2 interactions

open access: yesFEBS Letters, EarlyView.
The crystal structure of abMreC reveals a conserved two β‐barrel architecture and provides structural insights into its role within the bacterial elongasome. The abMreC–abPBP2 complex model identifies the molecular basis of MreC‐mediated PBP2 recognition, contributing to the regulation of peptidoglycan synthesis.
Hyunseok Jang   +4 more
wiley   +1 more source

Clinical Response of Meropenem versus Meropenem and Azithromycin in Extensively Drug-Resistant Salmonella

open access: yesPakistan Armed Forces Medical Journal
Objectives: To compare the clinical response of Meropenem versus a combination of Meropenem and Azithromycin in Extensively Drug-Resistant Salmonella. Study Design: Quasi-experimental study. Place and Duration of Study: Tertiary Care Hospital, Malir
Muhammad Ameen   +5 more
doaj   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

open access: yesFEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta   +3 more
wiley   +1 more source

Pharmacological modulation and manipulation of cancer drug resistance [PDF]

open access: yes, 2010
The aim of this project was to investigate pharmacological methods of overcoming resistance in cancer. Novel compounds, targeted therapies and non-steroidal anti-inflammatory drugs (NSAIDs) were examined for their potential to modulate and manipulate ...
Devery, Aoife
core   +2 more sources

Indole derivatives display antimicrobial and antibiofilm effects against extensively drug-resistant Acinetobacter baumannii

open access: yesMicrobiology Spectrum
Acinetobacter baumannii is a critical priority gram-negative bacterial species featured with multidrug resistance and biofilm formation. This study screened 46 indole derivative agents for their antimicrobial activities against clinical isolates of ...
Junwei Li   +3 more
doaj   +1 more source

Structure‐forward targeting of claudins with synthetic binders

open access: yesFEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Upcoming Multi-drug-Resistant and Extensively Drug-Resistant Bacteria

open access: yesResearch in Molecular medicine, 2022
Multi-drug-resistant (MDR) and extensively drug-resistant (XDR) bacteria are becoming a serious global health issue, which may soon become untreatable by clinicians. Since the invention of antibiotics, inappropriate consumption, non-prescribed drugs, overuse, and hoarding have caused the rapid emergence of MDR and XDR bacteria.
openaire   +2 more sources

Challenges of drug resistance in the management of pancreatic cancer [PDF]

open access: yes, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Naomi Walsh   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy